期刊
CANNABIS AND CANNABINOID RESEARCH
卷 6, 期 4, 页码 266-274出版社
MARY ANN LIEBERT, INC
DOI: 10.1089/can.2021.0041
关键词
cannabidiol; anti-emetic; behavior; CBD; phytocannabinoids
资金
- Natural Sciences and Engineering Research Council of Canada [NSERC-03629]
- Canadian Institutes of Health Research [CIHR-388239]
This study reviews the effectiveness of CBD, CBDA, and CBDA-ME in managing nausea and vomiting, and discusses the potential role of CBD in treating cannabinoid hyperemesis syndrome. The findings suggest the need for clinical trials to evaluate the ability of these compounds to reduce nausea and/or vomiting.
Introduction: Nausea and vomiting are the most distressing symptoms reported by oncology patients undergoing anticancer treatment. With the currently available treatments, vomiting and especially nausea remain problematic, highlighting the need for alternative treatments. Discussion: Here we review in vitro and in vivo evidence for the effectiveness of the nonpsychoactive cannabinoid cannabidiol (CBD) in managing nausea and vomiting. In addition, we also review the evidence for CBD's acidic precursor, cannabidiolic acid (CBDA), and a methylated version of CBDA (CBDA-ME) in these phenomena. Finally, we explore the potential role of CBD in the treatment of cannabinoid hyperemesis syndrome. Conclusions: CBD has demonstrated efficacy in reducing nausea and vomiting, with CBDA and CBDA-ME being more potent. The data suggest a need for these compounds to be evaluated in clinical trials for their ability to reduce nausea and/or vomiting.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据